[go: up one dir, main page]

MXPA03005515A - Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1. - Google Patents

Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.

Info

Publication number
MXPA03005515A
MXPA03005515A MXPA03005515A MXPA03005515A MXPA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A
Authority
MX
Mexico
Prior art keywords
mglur
azepine
thieno
pyrazine
benzo
Prior art date
Application number
MXPA03005515A
Other languages
English (en)
Inventor
Binggeli Alfred
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03005515A publication Critical patent/MXPA03005515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MXPA03005515A 2000-12-22 2001-12-11 Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1. MXPA03005515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128329 2000-12-22
PCT/EP2001/014527 WO2002051418A1 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists

Publications (1)

Publication Number Publication Date
MXPA03005515A true MXPA03005515A (es) 2003-09-25

Family

ID=8170787

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005515A MXPA03005515A (es) 2000-12-22 2001-12-11 Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.

Country Status (17)

Country Link
US (1) US6586422B2 (es)
EP (1) EP1345609B1 (es)
JP (1) JP4077319B2 (es)
KR (1) KR100545906B1 (es)
CN (1) CN1260226C (es)
AR (1) AR032379A1 (es)
AT (1) ATE297734T1 (es)
AU (1) AU2002216095B2 (es)
BR (1) BR0116378A (es)
CA (1) CA2432077C (es)
DE (1) DE60111568T2 (es)
DK (1) DK1345609T3 (es)
ES (1) ES2243400T3 (es)
MX (1) MXPA03005515A (es)
PT (1) PT1345609E (es)
WO (1) WO2002051418A1 (es)
ZA (1) ZA200304557B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5188986B2 (ja) * 2006-01-19 2013-04-24 アサーシス， インク． セロトニン５−ｈｔ２ｃ受容体のリガンドとしてのチオフェニルおよびピロリルアゼピンならびにこの使用
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101100864B1 (ko) * 2009-06-12 2012-01-02 양준호 자동차 광택기용 광택패드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136654A1 (de) 1981-09-16 1983-03-31 Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete
AU2642699A (en) * 1998-03-03 1999-09-20 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
DK1117403T3 (da) * 1998-10-02 2004-04-13 Sibia Neurosciences Inc MGLUR5-antagonister til behandling af smerte og angst
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
ATE254614T1 (de) * 1999-08-06 2003-12-15 Hoffmann La Roche Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors

Also Published As

Publication number Publication date
ATE297734T1 (de) 2005-07-15
CA2432077A1 (en) 2002-07-04
PT1345609E (pt) 2005-08-31
US20020123488A1 (en) 2002-09-05
EP1345609B1 (en) 2005-06-15
DE60111568D1 (de) 2005-07-21
ES2243400T3 (es) 2005-12-01
WO2002051418A1 (en) 2002-07-04
KR100545906B1 (ko) 2006-01-26
BR0116378A (pt) 2003-10-28
DE60111568T2 (de) 2006-05-11
JP4077319B2 (ja) 2008-04-16
DK1345609T3 (da) 2005-10-03
AU2002216095B2 (en) 2005-12-01
JP2004517850A (ja) 2004-06-17
ZA200304557B (en) 2004-09-13
CN1487831A (zh) 2004-04-07
CN1260226C (zh) 2006-06-21
US6586422B2 (en) 2003-07-01
CA2432077C (en) 2011-01-18
EP1345609A1 (en) 2003-09-24
AR032379A1 (es) 2003-11-05
KR20030062444A (ko) 2003-07-25

Similar Documents

Publication Publication Date Title
PT1589017E (pt) Derivados de epotilona modificados na posição 12,13
ZA200204380B (en) Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives.
MXPA02007232A (es) Derivados aminados de dihidro-1,3,5-triazina y sus ojos terapeuticos.
MA26831A1 (fr) Derives de benzodiazepine."
IL162377A0 (en) 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
IL139808A0 (en) Novel benzopyran or thiobenzopyran derivatives
GB2361235B (en) 2,2,6,6 Diethyl-dimethyl-1-alkoxy-piperidine compounds and their corresponding 1-oxides
MXPA03005515A (es) Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.
IL155103A0 (en) Substituted c-cyclohexylmethylamine derivatives
AU2489002A (en) Benzofuran and benzothiophene derivatives
EP1274431A4 (en) 10,11-DIFLUOROMETHYLENE DIOXYCAMTOTHECINE COMPOUNDS WITH TOPOISOMERASE-I INHIBITION
ZA200203275B (en) H-annellated benzo[f]chromenes.
PL364873A1 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
AU8177801A (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
MXPA02005070A (es) 1-benzazepinas sustituidas y derivados de las mismas.
PT1129079E (pt) Derivados de triazina 2,4-dissubstituidos
ZA200102392B (en) 1,2-Substituted 2,3-dihydro-1H-5,9-dioxacyclohepta [f] inden-7-ones and 7-substituted benzo [b] [1,4] dioxepin-3-ones.
AU7815201A (en) Synthetic salicylihalamides, apicularens and derivatives thereof
MXPA03002734A (es) Derivados de 5-amino-1-penten-3-ol sustituidos.
GB2378256B (en) The pit
ZA99171B (en) Piperazino derivatives as neurokinin antagonists.
HUP0201308A3 (en) Imidazo-containing heterocyclic compounds, their compositions and uses
ZA200202868B (en) Use of thienopyrimidines.
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
GB2350361B (en) 3,4,5-tricyanophenyl derivatives

Legal Events

Date Code Title Description
FG Grant or registration